Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05746182 · ClinicalTrials.gov registry record
Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms
A clinical trial of Pancreatic Neuroendocrine Neoplasm, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- 300
- Enrollment target
- 3
- Study locations
NCT05746182: Recruiting study of Pancreatic Neuroendocrine Neoplasm, sponsored by University of California, San Francisco.
NCT05746182 is a study of Pancreatic Neuroendocrine Neoplasm that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 300 participants. The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05746182, a study of Pancreatic Neuroendocrine Neoplasm, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a prospective observational multi-center pilot study of germline testing for participants receiving care at University of California participating locations with a new or existing diagnosis of Pancreatic Neuroendocrine Neoplasms (PanNEN). This protocol is an extension of existing Genetic Testing Station efforts at University of California, San Francisco (UCSF)
Primary Outcome
The overall percentage of participants with pathogenic, or likely pathogenic germline mutations will be reported with 95% confidence intervals
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Hereditary Cancer Panel
Study Locations (3)
California
- University of California, Los Angeles - Los Angeles
- Univeristy of California, San Diego - San Diego
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-04-07 |
| Est. Completion | 2026-12-31 |
What NCT05746182 shows while recruiting
NCT05746182 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Pancreatic Neuroendocrine Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Hereditary Cancer Panel is the first listed.
NCT05746182 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05746182 about?
NCT05746182 is a clinical study titled "Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms". This is a prospective observational multi-center pilot study of germline testing for participants receiving care at University of California participating locations with a new or existing diagnosis of Pancreatic Neuroendocrine Neoplasms (PanNEN). This protocol is an extension of existing Genetic Tes...
What is the current status of trial NCT05746182?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2023-04-07. Estimated completion is 2026-12-31.
What conditions does trial NCT05746182 study?
This clinical trial studies the following conditions: Pancreatic Neuroendocrine Neoplasm.
What interventions are being tested in trial NCT05746182?
The interventions under investigation include: Hereditary Cancer Panel (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05746182?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05746182 being conducted?
This trial has 3 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Neuroendocrine Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI